FPP 004X
Alternative Names: FPP-004; FPP-004XLatest Information Update: 25 Aug 2023
At a glance
- Originator FunPep; Osaka University
- Class Antiallergics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Seasonal allergic rhinitis
Most Recent Events
- 18 Jul 2023 FPP 004X is available for licensing as of 18 Jul 2023. https://www.funpep.co.jp/en/
- 18 Jul 2023 Preclinical trials in Seasonal allergic rhinitis (Parenteral) in Japan (FunPep pipeline, July 2023)